Kalfoset calcium, phosphorus, magnesium

Kalfoset ^®  belongs to a group of products containing calcium, phosphorus, magnesium.

The effect of the drug is determined by the effect of the constituent components. Calcium is involved in the formation of bone tissue (prevents the risk of rickets and osteodystrophy), blood coagulation, in the regulation of the processes of nerve conduction and muscle contractions, in maintaining stable cardiac activity. It has a tonic, antitoxic effect.

Phosphorus is the main constituent of bone tissue, nucleoproteins and phospholipids. He takes part in all the processes of assimilation in the body of the animal, has a positive effect on the metabolism in the tissues of the body.

Magnesium participates in the metabolism of phosphorus and carbohydrates as a coenzyme. When administered parenterally, it blocks neuromuscular transmission and prevents the development of seizures.

The active ingredients of Kalfoset ^®  are in a physiological ratio, are well and quickly absorbed after parenteral administration.

According to the degree of impact on the body, Kalfoset ^® , according to GOST 12.1.007-76, refers to low-hazard substances (hazard class 4).

Kalfoset ^{® is}  used in a complex of measures for the treatment and prevention of diseases of farm animals with:

• tetany (during pregnancy, lactation, during transportation, grazing, etc.),
• paresis caused by a lack of calcium and phosphorus; metabolic disorders of calcium, phosphorus, magnesium (rickets, osteodystrophy, osteomalacia, etc.),
• poisoning with lead, fluorine, oxalic acid (as an additional agent in complex treatment),
• toxicosis, allergies.

Kalfoset ^{® is}  contraindicated in hypercalcemia, acidosis, severe renal dysfunction, atrial fibrillation, hypersensitivity to the components of the drug.

The drug is administered to animals intravenously, intramuscularly or subcutaneously in the following doses:

Kalfoset ^{® is}   administered to animals once. It is allowed to re-use the drug after 24 hours in the same doses.

For the prevention of disturbances of calcium metabolism, and magnesium fasfora during pregnancy, lactation, and rickets young farm animals Kalfoset ^®   applied singly at the recommended doses

In cattle, Kalfoset ^®  is injected subcutaneously into the same place no more than 50 ml of the drug, intramuscularly – no more than 25 ml. Pigs, sheep and goats – intramuscularly in the same place – no more than 15 ml of the drug. The drug is administered intravenously slowly and evenly.

Overdose symptoms have not been identified in animals.

The peculiarities of the action of the drug during its first use have not been established.

The use of Kalfoset ^®  does not exclude the use of other medicines.

There are no side effects and complications in animals when using the drug in accordance with this instruction, no contraindications have been established.

It is  not recommended to prescribe Kalfoset ^® to animals simultaneously with digitalis preparations, vitamin D and its analogues.

Products of animal origin after the application of Kalfoset ^®  are used on a general basis.

The drug is produced in the form of a sterile solution, packaged in hermetically sealed dark glass vials, sealed with rubber stoppers, reinforced with aluminum caps.

The shelf life of the medicinal product, subject to storage conditions, is 3 years from the date of manufacture, after the first opening of the bottle – no more than 28 days.

It is forbidden to use Kalfoset ^®  after the expiration date.

Store the drug in a closed manufacturer’s packaging in a dry place protected from direct sunlight, separately from food and feed, at a temperature from +5 ^o C to +25 ^o C.